GTBP · GT Biopharma, Inc.
$0.32
-0.01 (-2.61%)
At close · Aug 5
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$11.45M
Shares
36.06M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael Breen | CEO | $1,727,646 |
| Alan Urban | CFO | $739,310 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael Breen | CEO | $1,186,972 |
| Alan Urban | CFO | $377,782 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Breen | CEO | $1,525,834 |
| Manu Ohri | CFO | $1,129,671 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Breen | CEO | $1,892,293 |
| Manu Ohri | CFO | $944,544 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Anthony Cataldo | CEO | $10,494,677 |
| Michael Breen | CEO | $2,827,703 |
| Michael Handelman | CFO | $2,810,367 |
| Dr. Gregory Berk | CEO | $1,424,519 |
| Dr. Gavin Choy | CFO | $961,818 |
| Manu Ohri | CFO | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Anthony Cataldo | CEO | $428,817 |
| Michael Handelman | CFO | $74,833 |
| Dr. Gregory Berk | CEO | — |
| Michael Breen | Chairman | — |
| Dr. Gavin Choy | CFO | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David C. Mun-Gavin | non-employee director of the Board | Appointed | 2025-06-11 |
| Andrew Ritter | member of the board of directors | Resigned | 2025-06-11 |
| Bruce Wendel | member of the Board and all committees thereof | Resigned | 2025-05-13 |
| Andrew Ritter | non-employee director | Appointed | 2025-05-13 |
| Rajesh Shrotriya | member of the Board and all committees thereof | Resigned | 2025-05-13 |
| Hilary Kramer | non-employee director | Appointed | 2025-05-13 |
| Michael Breen | Chief Executive Officer | Appointed | 2025-05-05 |
| Dr. Jeffrey Miller | Consulting Senior Medical Director | Appointed | 2024-09-16 |
| Alan L. Urban | Chief Financial Officer | Appointed | 2024-06-07 |
| Manu Ohri | Chief Financial Officer | Terminated | 2024-06-07 |
Key facts
CIK
109657
CUSIP
36254L308
13F (30d)
18 filings
18 filers
Visit website
Investor relations